Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Inari Medical Background Information (This ... deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep ...

Inari shareholders are getting a fair price ... and has not really been a player in venous markets like pulmonary embolism (or PE), deep vein thrombosis (or DVT), limb ischemia, and the like ...

In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against other firms post strong gains amid Wall Street bloodbath. Wall Street’s main indices closed ...

Stryker acquires Inari Medical for $80/share ... for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. Also Read: Morgan Stanley Maintains Positive MedTech Outlook ...

Inari is poised to enhance Stryker's footprint ... These solutions are designed to treat peripheral vascular conditions such as pulmonary embolism and deep vein thrombosis. They claim to remove ...

Irvine, California-based Inari, which was founded in 2013, is a maker of devices and systems that treat patients suffering from a variety of blood clot conditions including pulmonary embolism, deep ...

NEW YORK, Jan 6 (Reuters) - Medical-device maker Stryker (SYK.N), opens new tab on Monday agreed to acquire Inari Medical (NARI.O), opens new tab, which makes devices that treat patients with ...

Inari’s product portfolio is complementary to Stryker’s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and ...